Genetics of Medication Sensitivity
Medication sensitivity refers to individual differences in drug responses, including efficacy, side effects, and toxicity. Genetic variants in drug-metabolising enzymes, drug transporters, and target receptors underlie most pharmacogenomic differences relevant to chronic illness management.
This page is for educational and informational purposes only. Not a diagnostic tool. Always consult a qualified healthcare provider.
What is Medication Sensitivity?
Patients with Long COVID and ME/CFS frequently report heightened sensitivity to medications, including common over-the-counter drugs. This may reflect impaired detoxification capacity, altered drug receptor sensitivity, or disrupted autonomic responses to pharmacological agents. Pharmacogenomics — the study of how genes influence drug responses — identifies variants in CYP450 enzymes, ABC transporters, and drug target genes that predict individual medication responses. Understanding these variants can support more personalised approaches to symptom management.
Biological pathways commonly discussed in relation to Medication Sensitivity
Research into Medication Sensitivity and Pharmacogenomics has highlighted several biological pathways that may be relevant. Genetic variants within these pathways may influence individual susceptibility, symptom severity, or the trajectory of the condition.
Cyp450 Metabolism
Cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9, CYP3A4) metabolise the majority of common medications. Variants create poor, intermediate, normal, and ultra-rapid metaboliser phenotypes with significant drug response implications.
Drug Transport
P-glycoprotein (ABCB1) and OATP1B1 (SLCO1B1) regulate drug distribution between tissues. Variants affect drug bioavailability, CNS penetration, and statin-related side effects.
Drug Receptor Variants
Variants in drug target genes (e.g. VKORC1 for warfarin, DPYD for fluoropyrimidines) alter drug efficacy or toxicity profiles. These are among the most clinically actionable pharmacogenomic findings.
Phase2 Conjugation
Phase II enzymes (NAT2, SULT1A1, UGT1A1) conjugate drug metabolites for excretion. Variants in these enzymes affect drug clearance rates and exposure to reactive metabolites.
Key genes studied in relation to Medication Sensitivity
The following genes have been studied in relation to Medication Sensitivity and Pharmacogenomics. These genes span the biological pathways most commonly discussed in this area of research.
14 genes total studied in relation to Medication Sensitivity across the ChronicDNA dataset.
Genetic variants commonly discussed
The following genetic variants (SNPs) are found in genes that have been studied in relation to Medication Sensitivity. Each variant represents a position in the genome where individuals may carry different alleles.
34 variants total across genes studied in relation to Medication Sensitivity.
How personal DNA data may provide educational insights
Consumer DNA files from 23andMe, AncestryDNA, and MyHeritage contain raw SNP data. When you upload your file to ChronicDNA, the analysis engine checks your genotype against a curated panel of 80+ genes selected for their relevance to Long COVID, ME/CFS, and connected biological pathways - some of which may relate to areas such as Medication Sensitivity.
This is not a diagnostic service. Genetic variants do not determine whether you have Medication Sensitivity, nor do they predict your clinical outcomes. The report is educational - it explains which variants you carry, what the research says about them, and how they fit into the biological pathways most relevant to chronic illness. All results should be discussed with a qualified healthcare provider.
Related conditions and pathways
Medication Sensitivity shares biological pathways and genetic associations with the following related conditions and areas of research.
Frequently asked questions
Why are Long COVID and ME/CFS patients often sensitive to medications?
Heightened medication sensitivity in chronic illness may reflect impaired CYP450 metabolism, dysregulated drug transport, altered autonomic responses to pharmacological agents, or post-infectious changes in drug receptor sensitivity. Genetic variants in metabolising enzymes may contribute to individual differences.
Which pharmacogenomic genes are most clinically relevant?
The most clinically studied genes are CYP2D6, CYP2C19, CYP2C9, VKORC1, SLCO1B1, DPYD, and TPMT. These influence responses to antidepressants, anticoagulants, statins, and chemotherapy agents.
What does being a poor metaboliser mean for medication use?
A poor metaboliser has reduced or absent activity of a CYP450 enzyme, causing slower drug clearance. This typically results in higher plasma drug levels, prolonged drug effects, and increased risk of side effects for medications primarily metabolised by that enzyme.
Can pharmacogenomic information be useful in managing Long COVID symptoms?
Understanding individual drug metabolism may help anticipate responses to medications used symptomatically in Long COVID management. ChronicDNA provides educational pharmacogenomic insights — any medication decisions should be made with a qualified healthcare provider.
Explore DNA insights
If you already have DNA data from 23andMe, AncestryDNA, or MyHeritage, upload your raw file to ChronicDNA and receive a personalised educational report covering genes studied in relation to Medication Sensitivity and connected biological pathways.
Get Your Personalised DNA ReportInformational and educational only · Not a diagnostic tool · GDPR compliant
14 genes · 34 variants analysed in relation to Medication Sensitivity